Finance

Lists
BSX:NYSE
Boston Scientific Corp
43,31 USD
-1,21%
(-0,53) 1D
43,55 USD
+0,55% (+0,24)
Pre-market
Closed: 13-окт., 16:00:05 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BSX...
Open
43,95 USD
High
44,15 USD
Low
42,46 USD
Mkt. cap
62,77 млд
Avg. vol.
19,54 млн
Volume
12,96 миң
P/E ratio
17,56
52-wk high
105,65 USD
52-wk low
41,38 USD
EPS
2,47 USD
Beta
0,58
Shares outstanding
1,45 млд
No. of employees
59 миң
Open
43,95 USD
High
44,15 USD
Low
42,46 USD
Mkt. cap
62,77 млд
Avg. vol.
19,54 млн
Volume
12,96 миң
P/E ratio
17,56
52-wk high
105,65 USD
52-wk low
41,38 USD
EPS
2,47 USD
Beta
0,58
Shares outstanding
1,45 млд
No. of employees
59 миң
News stories
From web sources and news partners
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp
CEOMichael F. Mahoney
Employees59 миң
Founded1979-ж., 29-июн.
HeadquartersМарлборо, Массачусетс, Америка Кошмо Штаттары
SectorMedical device
Analyst ratings
Based on 22 analysts giving stock ratings to BSX in the past 3 months
Strong buy
Buy
18
Hold
4
Sell
0
12-month forecast
Based on 22 Wall Street analysts offering 12 month price targets for BSX in the last 3 months.
Highest
Current 43,31 USD
70,00 USD (+61,63%)
Average
57,30 USD (+32,30%)
Lowest
48,00 USD (+10,83%)
Analyst
Recommendation
Action
Price target
Projected
Date
Anthony Petrone
Mizuho Securities
Buy
Reiterated
55,00 USD
+27%
10/13/2026
Marie Thibault
BTIG
Buy
Reiterated
56,00 USD
+29,3%
10/12/2026
Mike Kratky
Leerink Partners
Buy
Reiterated
55,00 USD
+27%
10/12/2026
Christopher Pasquale
Barclays
Hold
Initiated
48,00 USD
+10,8%
10/07/2026
Matt Miksic
Barclays
Hold
Maintained
48,00 USD
+10,8%
10/07/2026
Joanne Wuensch
Citi
Hold
Reiterated
48,00 USD
+10,8%
10/05/2026
Unknown Analyst
Bernstein
Buy
Reiterated
54,00 USD
+24,7%
10/02/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
56,00 USD
+29,3%
10/01/2026
Kendall Au
RBC Capital
Buy
Maintained
70,00 USD
+61,6%
10/01/2026
Larry Biegelsen
Wells Fargo
Hold
Reiterated
48,00 USD
+10,8%
09/24/2026
Suraj Kalia
Oppenheimer
Buy
Reiterated
65,00 USD
+50,1%
09/21/2026
Travis Steed
Bank of America Securities
Buy
Maintained
54,00 USD
+24,7%
09/20/2026
Josh Jennings
TD Cowen
Buy
Maintained
56,00 USD
+29,3%
09/17/2026
Matthew Taylor
Jefferies
Buy
Maintained
60,00 USD
+38,5%
09/11/2026
Richard Newitter
Truist Financial
Buy
Maintained
-
-
09/09/2026
David Toung
Argus Research
Hold
Downgraded
-
-
07/30/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
55,00 USD
+27%
07/30/2026
Pito Chickering
Deutsche Bank
Buy
Maintained
60,00 USD
+38,5%
07/30/2026
David Rescott
Robert W. Baird
Buy
Maintained
56,00 USD
+29,3%
07/30/2026
William Plovanic
Canaccord Genuity
Buy
Reiterated
66,00 USD
+52,4%
07/30/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
70,00 USD
+61,6%
07/29/2026
Michael Matson
Needham
Buy
Maintained
57,00 USD
+31,6%
07/29/2026
Patrick Wood
UBS
Buy
Maintained
67,00 USD
+54,7%
07/30/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
60,00 USD
+38,5%
07/29/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
85,00 USD
+96,3%
07/27/2026
David Roman
Goldman Sachs
Buy
Maintained
57,00 USD
+31,6%
07/14/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
65,00 USD
+50,1%
06/12/2026
Stephanie Elghazi
Bank of America Securities
Buy
Maintained
68,00 USD
+57%
06/09/2026
Michael Polark
Wolfe Research
Hold
Downgraded
-
-
05/29/2026
Hans Engel
Erste Group
Hold
Reiterated
-
-
04/01/2026
Jayson Bedford
Raymond James
Buy
Maintained
88,00 USD
+103,2%
03/27/2026
Danielle Antalffy
UBS
Buy
Reiterated
105,00 USD
+142,4%
03/17/2026
Lee Hambright
Bernstein
Buy
Maintained
112,00 USD
+158,6%
02/05/2026
Last report
2026-ж., 29-июл.
Fiscal period
Q2 2026
0,86 USD / 0,83 USD
+3,86%beat
Revenue / Est. (USD)
5,44 млд / 5,37 млд
+1,42%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
5,06 млд
5,29 млд
5,20 млд
5,44 млд
Cost of goods sold
1,54 млд
1,61 млд
1,60 млд
1,61 млд
Cost of revenue
1,54 млд
1,61 млд
1,60 млд
1,61 млд
Research and development expenses
514,00 млн
569,00 млн
516,00 млн
554,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,74 млд
1,83 млд
1,78 млд
1,80 млд
Operating expense
2,48 млд
2,63 млд
2,53 млд
2,59 млд
Total operating expenses
4,02 млд
4,24 млд
4,13 млд
4,20 млд
Operating income
1,05 млд
1,04 млд
1,07 млд
1,25 млд
Other non operating income
-16,00 млн
28,00 млн
28,00 млн
-6,00 млн
EBT including unusual items
938,00 млн
700,00 млн
1,16 млд
1,06 млд
EBT excluding unusual items
935,00 млн
1,01 млд
999,00 млн
1,14 млд
Income tax expense
183,00 млн
30,00 млн
-176,00 млн
155,00 млн
Effective tax rate
19,51%
4,29%
-15,13%
14,62%
Other operating expenses
-
-
-
-
Net income
755,00 млн
672,00 млн
1,34 млд
907,00 млн
Net profit margin
14,91%
12,71%
25,77%
16,67%
Earnings per share
0,75
0,80
0,80
0,86
Interest and investment income
-
29,00 млн
-
11,00 млн
Interest expense
-87,00 млн
-90,00 млн
-90,00 млн
-96,00 млн
Net interest expenses
-87,00 млн
-61,00 млн
-90,00 млн
-85,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,39 млд
1,41 млд
1,42 млд
1,60 млд
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору